Modulation of circulating inflammatory biomarkers by SGLT2 inhibitors in diabetic patients with acute myocardial infarction: A quantitative meta-analysis of laboratory evidence.

Authors

Jia Xu, Yuanhong Jie, Tao Dong, Qi Li, Xiaobing Liu

Published in

Journal of medical biochemistry. Volume 45. Issue 6. Pages 1207-1221. Jun 16, 2026.

Abstract

Acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM) is characterized by an exaggerated inflammatory response and adverse myocardial remodeling. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) have demonstrated cardiometabolic benefits; however, their effects on circulating inflammatory biomarkers in diabetic AMI remain inconsistent. This meta-analysis aimed to quantitatively evaluate laboratory-based evidence regarding the modulation of key inflammatory markers by SGLT2-I therapy in this high-risk population.
A systematic search of PubMed, ScienceDirect, Cochrane Library, Web of Science, CNKI, and Wanfang databases was conducted up to December 2025. Randomized controlled trials and prospective cohort studies involving T2DM patients with AMI were included. Primary laboratory endpoints were circulating inflammatory biomarkers (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP], tumor necrosis factor-a [TNF-a]). Secondary outcomes included left ventricular ejection fraction (LVEF) and major adverse cardiovascular events (MACE).

PMID:
42781614
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.